CIK 0000315545
- Non-accelerated filer
- Smaller reporting company
PROVECTUS BIOPHARMACEUTICALS, INC.
Sign in to watch- Ticker
- PVCT
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 900031917
- Phone
- +1 866-594-5999
- Business address
- 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929
- Former names
- PROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC, SPM GROUP INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-28 | Raines Heather CFO | Returned to the company · 8% Unsecured Convertible Promissory Note due 2022 | −0 | $50,000.00 | $0 | |
| 2024-02-27 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $180,000.00 | $0 | |
| 2024-02-27 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-02-27 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +37,744 | 1,046,572 | ||
| 2024-02-17 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-02-17 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +47,180 | 1,008,828 | ||
| 2024-02-15 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $75,000.00 | $0 | |
| 2024-02-02 | Raines Heather CFO | Returned to the company · 8% Unsecured Convertible Promissory Note due 2022 | −0 | $25,000.00 | $0 | |
| 2024-01-30 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $135,000.00 | $0 | |
| 2024-01-26 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-01-26 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +47,180 | 961,648 | ||
| 2024-01-12 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-01-12 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +47,180 | 914,468 | ||
| 2023-12-28 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $100,000.00 | $0 | |
| 2023-12-22 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-12-22 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +9,440 | 876,728 | ||
| 2023-12-19 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-12-19 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +37,760 | 867,288 | ||
| 2023-12-02 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-12-02 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +56,628 | 829,528 |
Page 9 of 17 · 329 trades